Inovio adds two to the leadership team; Adrian Woolfson is out at Sangamo
→ Entrenched in a legal battle with their manufacturer that’s evidently blocking them from making their Covid-19 vaccine candidate, Inovio is making some leadership changes. Gene Kim will be president of Inovio Asia, while Mammen (Anza) Mammen jumps aboard the biotech as SVP, clinical development, and is slated oversee development of Inovio’s DNA vaccine candidate INO-4800.
An ex-CFO at VGX Pharmaceuticals, Kim had previously been the CFO of AfreecaTV and video game developer WeMade Entertainment, both South Korean companies. And Mammen, who retired from the US Army with the rank of colonel, spent more than 6 years at Vical, becoming their SVP, clinical development, and prior to that role, was an infectious disease consultant and founding chief of the DoD’s pandemic warning team at Fort Detrick, MD.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.